$Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis$
QR Code

QR Code

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis

<b>Background/Objectives:</b> Classic Hodgkin lymphoma (cHL) is a predominantly curable B-cell malignancy. However, primary refractory and relapsed (R/R) cHL remain therapeutic challenges, especially in regions with high tuberculosis (TB) prevalence, where clinical and radiologic feature...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mohamed Nazem Alibrahim, Hussein Hammam, Antonino Carbone, Noor Alsaleh, Annunziata Gloghini
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Hemato
Subjects:	relapsed/refractory cHL Hodgkin disease tuberculosis immunotherapy stem cell transplantation
Online Access:	https://www.mdpi.com/2673-6357/6/2/12
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Tumor‐associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma
by: Maja Dam Andersen, et al.
Published: (2025-07-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Outcome of Pregnancy and Labour in a Patient with Hodgkin’s Lymphoma (Clinical Case)
by: A. A. Borscheva, et al.
Published: (2019-09-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Observations on seasonal occurrence in lymphomas with proven or presumed infectious etiology
by: Ioannis Anagnostopoulos, et al.
Published: (2025-07-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection
by: L. S. Khayrullina, et al.
Published: (2022-07-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experience
by: N. V. Zhukov, et al.
Published: (2014-09-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan
by: John G. Gribben, et al.
Published: (2025-07-01)

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
by: M. V. Solovev, et al.
Published: (2024-12-01)

Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial
by: Qihua Zou, et al.
Published: (2025-05-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2<sup>nd</sup> line treatment before autologous hematopoietic stem cell transplantation (preliminary results)
by: A. A. Mamedova, et al.
Published: (2022-07-01)

Hodgkin lymphoma: current conception and unresolved questions
by: Gurtovoj V.A., et al.
Published: (2010-01-01)

Refractories /
by: Norton, Frederick Harwood
Published: (1968)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy
by: S. K. Zyryanov, et al.
Published: (2024-08-01)

New approaches for combined therapy of Hodgkin's lymphoma
by: P. V. Dacenko, et al.
Published: (2022-11-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)

Satellite remote sensing of algal blooms in seagoing river in Eastern China
by: Zili Zhang, et al.
Published: (2025-07-01)